Colaboración especial
¿Constituirán en el futuro los radioligandos de 68Ga-PSMA la única elección de la Medicina Nuclear para el cáncer de próstata? Actualización clínica
Will 68Ga PSMA-radioligands be the only choice for nuclear medicine in prostate cancer in the near future? A clinical update
V. Cuccurulloa,
, G.D. di Stasioa, L. Evangelistab, A. Ciarmielloc, L. Mansid
Autor para correspondencia
a Nuclear Medicine Unit, Department of Clinical and Experimental Internistic «F. Magrassi - A. Lanzara» - University of Campania Luigi Vanvitelli, Napoli, Italia
b Radiotherapy and Nuclear Medicine Unit, Istituto Oncologico Veneto (IOV-IRCCS), Padova, Italia
c Department of Nuclear Medicine, S. Andrea Hospital, La Spezia, Italia
d Interuniversity Research Centre on Sustainable Development (CIRPS), Roma-Napoli, Italia
Leído
450
Vecesse ha leído el artículo
93
Total PDF
357
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 2 | 2 | 2 | 4 |
| 2025 1 | 4 | 2 | 6 |
| 2024 3 | 1 | 2 | 3 |
| 2023 11 | 1 | 4 | 5 |
| 2023 6 | 1 | 0 | 1 |
| 2023 5 | 2 | 1 | 3 |
| 2023 4 | 6 | 0 | 6 |
| 2023 3 | 1 | 2 | 3 |
| 2022 5 | 3 | 0 | 3 |
| 2022 3 | 3 | 4 | 7 |
| 2022 2 | 1 | 0 | 1 |
| 2021 1 | 1 | 2 | 3 |
| 2021 11 | 1 | 2 | 3 |
| 2021 10 | 146 | 2 | 148 |
| 2021 4 | 1 | 0 | 1 |
| 2021 2 | 4 | 2 | 6 |
| 2020 12 | 3 | 2 | 5 |
| 2020 11 | 1 | 2 | 3 |
| 2020 10 | 2 | 4 | 6 |
| 2020 9 | 3 | 3 | 6 |
| 2020 8 | 0 | 2 | 2 |
| 2020 7 | 1 | 0 | 1 |
| 2020 2 | 2 | 2 | 4 |
| 2019 12 | 1 | 4 | 5 |
| 2019 11 | 57 | 2 | 59 |
| 2019 10 | 33 | 4 | 37 |
| 2019 7 | 0 | 2 | 2 |
| 2019 6 | 2 | 2 | 4 |
| 2019 3 | 1 | 0 | 1 |
| 2019 2 | 1 | 2 | 3 |
| 2019 1 | 2 | 4 | 6 |
| 2018 12 | 1 | 0 | 1 |
| 2018 11 | 1 | 2 | 3 |
| 2018 10 | 14 | 8 | 22 |
| 2018 9 | 2 | 6 | 8 |
| 2018 8 | 2 | 1 | 3 |
| 2018 7 | 3 | 0 | 3 |
| 2018 6 | 3 | 1 | 4 |
| 2018 5 | 4 | 1 | 5 |
| 2018 4 | 9 | 0 | 9 |
| 2018 3 | 31 | 12 | 43 |
| 2018 2 | 0 | 2 | 2 |
Mostrar todo
